Lucid Diagnostics Inc. (LUCD) stock
Close on Nov 12, 2026Market cap $84.61MP/E –Yield –
Lucid Diagnostics Inc. grew revenue 23.6% to $5.44M over the twelve months to Sep 30, 2026. Free cash flow was -$51.83M. At the latest close the market valued the company at $84.61M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $84.61M
- P/E ratio
- –
- Price to sales
- 15.56
- Price to book
- 14.26
- Dividend yield
- –
- Free cash flow yield
- -61.26%
Fundamentals
- Revenue
- $5.44M
- Net income
- -$48.54M
- EPS, diluted
- -$0.40
- Free cash flow
- -$51.83M
- Book value per share
- $0.03
- Diluted shares
- 191M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.38
- Open
- $0.40
- Day's range
- $0.38 – $0.43
- Volume
- 2,358,820
- Average volume (20 days)
- 13,021,154
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.01
- 52-week range
- $0.30 – $1.63
- RSI (14 days)
- 37.1
- Volatility (1 year)
- 77.7%
- Relative volume
- 0.44×
- WACC
- 9.9%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LUCD | S&P 500 | Difference | LUCD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.3% | -2.7% | −27.6 pts | ||
| 3 months | -57.7% | -1.7% | −56.0 pts | ||
| Year to date | -61.8% | +11.9% | −73.7 pts | ||
| 1 year | -62.5% | +12.0% | −74.5 pts | ||
| 3 years | -64.1% | +78.2% | −142.3 pts | -28.9% | +21.2% |
| 5 years | -95.7% | +73.2% | −169.0 pts | -46.8% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lucid Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Update
About Lucid Diagnostics
Surgical & Medical Instruments & Apparatus
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on preventing esophageal adenocarcinoma in patients with gastroesophageal reflux disease. Its core products include EsoCheck, a noninvasive swallowable balloon capsule catheter used for targeted esophageal cell sampling, and EsoGuard, a targeted next-generation sequencing DNA test designed to detect esophageal precancer. The company markets its diagnostic products to primary care and gastroenterology physicians, self-insured employers, unions, and healthcare systems, while also providing testing through commercial health network arrangements and a direct-to-consumer telemedicine program.
Company profile, executives and historyLucid Diagnostics stock: common questions
What is Lucid Diagnostics's stock price?
LUCD closed at $0.42 on Nov 12, 2026, up 9.15% on the day. Over the past 52 weeks it traded between $0.30 and $1.63.
What is Lucid Diagnostics's market cap?
Lucid Diagnostics was worth $84.61M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LUCD's P/E ratio?
Lucid Diagnostics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.40), so it has no meaningful P/E ratio.
How much revenue does Lucid Diagnostics make?
Lucid Diagnostics reported revenue of $5.44M for the twelve months to Sep 30, 2026, up 23.6% from a year earlier.
Does Lucid Diagnostics pay a dividend?
No. Lucid Diagnostics has not paid a cash dividend over the last twelve months.
When does Lucid Diagnostics report earnings next?
Lucid Diagnostics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has LUCD stock performed over the past year?
Including dividends, LUCD returned -62.5% over the past year, against +12.0% for the S&P 500.
How many LUCD shares are sold short?
15M shares were sold short at the latest FINRA report, 9.80% of the float, or 1.0 days of average trading volume.
Who are Lucid Diagnostics's competitors?
Companies most similar to Lucid Diagnostics by business, industry and size include ECIA, CNSY, INBS, RNXT, NSPR.
See a number that looks wrong?